-
13:00
Building a first EU Ecosystem for Gene therapy development for rare diseases. The why and the how?
-
David Morrow
(Senior Scientific Program Manager ATMP EATRIS)
-
13:20
Workflow solutions for more efficient, reproducible, and standardized GT development to the clinic
-
Eleni Papanikolaou
(Strategic Lead– Miltenyi Biotech)
-
13:40
In depth product characterization of ATMPs, standardized assays for efficacy and safety and technology transfer to GMP
-
Leila Amini
(Head of Regulatory Affairs, Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin)
-
14:00
The need for biomarker platform according to GCLP guidelines to monitor therapy response
-
Hans Dieter Volk
(Senior Professor-Charite Universitätsmedizin Berlin, Inst.Med.Immunology)